Seeking Alpha
22 Jul 2026, 17:50 UTC · 59m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Curis reported positive data from a combination study of emavusertib in patients with primary CNS lymphoma. — Positive clinical data for a lead drug candidate is a primary driver of biotech valuation and potential regulatory approval paths.
+0.80The study focused on emavusertib as a combination therapy specifically for primary CNS lymphoma. — Defining the target indication and therapeutic approach clarifies the market size and competitive landscape for the drug.
+0.30Which stocks this story touches
The company is discussing positive data from a combination study for Primary CNS Lymphoma.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
59m ago
